Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Shagisultanova, Elena
Wisinski, Kari B.
Gawryletz, Chelsea D.
Datko, Farrah M.
Medgyesy, Diana
Diamond, Jennifer R.
Borges, Virginia F.
Kabos, Peter
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer
    Dolgin, Elie
    CANCER DISCOVERY, 2019, 9 (01) : 6 - 7
  • [2] Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
    Batalini, Felipe
    Moulder, Stacy L.
    Winer, Eric P.
    Rugo, Hope S.
    Lin, Nancy U.
    Wulf, Gerburg M.
    JCO PRECISION ONCOLOGY, 2020, 4 : 572 - 578
  • [3] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [4] Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
    Raphael, Ari
    Salmon-Divon, Mali
    Epstein, Jessica
    Zahavi, Tamar
    Sonnenblick, Amir
    Shachar, Shlomit S.
    GENES, 2022, 13 (10)
  • [5] Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer.
    Shen, Sherry
    Salehi, Erica
    Farooki, Azeez
    Flory, James
    Williams, Dominiq
    Carpio, Andrea
    Chang, Cassandra
    Lacouture, Mario E.
    Andreopoulou, Eleni
    Sardesai, Sagar D.
    Jhaveri, Komal L.
    Cantley, Lewis Clayton
    Goncalves, Marcus D.
    Iyengar, Neil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
    Jhaveri, Komal
    Drago, Joshua Z.
    Shah, Payal Deepak
    Wang, Rui
    Pareja, Fresia
    Ratzon, Fanni
    Iasonos, Alexia
    Patil, Sujata
    Rosen, Neal
    Fornier, Monica N.
    Sklarin, Nancy T.
    Chandarlapaty, Sarat
    Modi, Shanu
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3867 - 3875
  • [7] Targeting PIK3CA-mutant advanced breast cancer in the clinical setting
    Chopra, Neha
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2017, 18 (07): : 842 - 843
  • [8] A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
    Sara Donzelli
    Mario Cioce
    Andrea Sacconi
    Francesca Zanconato
    Theodora Daralioti
    Frauke Goeman
    Giulia Orlandi
    Simona Di Martino
    Vito Michele Fazio
    Gabriele Alessandrini
    Stefano Telera
    Mariantonia Carosi
    Gennaro Ciliberto
    Claudio Botti
    Sabrina Strano
    Stefano Piccolo
    Giovanni Blandino
    Molecular Cancer, 21
  • [9] Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
    Ulrich, Lara
    Okines, Alicia F. C.
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 361 - 381
  • [10] PIK3CA-Mutant Breast Cancer Metastatic Patient-Derived Organoid Approach to Evaluate Alpelisib Treatment for Multiple Secondary Lesions
    Cioce, M.
    Donzelli, S.
    Sacconi, A.
    Zanconato, F.
    Daralioti, T.
    Orlandi, G.
    Di Martino, S.
    Fazio, V. M.
    Alessandrini, G.
    Telera, S.
    Carosi, M.
    Ciliberto, G.
    Goeman, F.
    Botti, C.
    Strano, S.
    Piccolo, S.
    Blandino, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (06): : S54 - S54
12345